Vision ReNu Corp. Bringing Taiwan’s Innovation to Global Brain Health

Source: 瑞光生醫科技股份有限公司 ( Healthcare+ Expo- booth no.: L1019)

Vision ReNu Corp. Bringing Taiwan’s Innovation to Global Brain Health

In response to the rapidly increasing global prevalence of depression and neurological disorders, Vision ReNu Corp. leverages its advanced medical device R&D expertise to deliver next-generation brain health solutions designed around clinical needs.

After years of intensive development, Vision ReNu has successfully introduced Taiwan’s first transcranial magnetic stimulation (TMS) system dedicated to Depressive Disorder treatment — MagRenu™ TMS. In 2025, MagRenu™ TMS received regulatory approval from Taiwan Food and Drug Administration (TFDA) (Medical Device Registration No. 008433), marking a major milestone in Taiwan’s neurostimulation and mental health technology landscape.

Precision Neurostimulation for Modern Clinical Practice

MagRenu™ TMS is powered by high-density pulsed magnetic field technology and supports multiple advanced and customizable stimulation protocols, including:

• Repetitive Transcranial Magnetic Stimulation (rTMS)

• Intermittent Theta Burst Stimulation (iTBS)

• Open mode of parameter settings for individualized treatment

This flexible platform enables clinicians to deliver non-invasive, targeted, safe, and highly reproducible neural modulation, improving precision, safety, and efficiency.

Designed for Real-World Clinical Needs

MagRenu™ TMS is specifically designed for adult patients with Major Depressive Disorder (MDD) who demonstrate inadequate response to conventional pharmacological therapy.

In parallel, TMS technology has been widely investigated and applied internationally in the management and prevention of multiple neuropsychiatric conditions, including:

• Insomnia

• Mild Cognitive Impairment (MCI)

• Dementia and Alzheimer’s disease

• Parkinson’s disease

• Other neurological and neuropsychiatric disorders

This positions MagRenu™ TMS as a versatile clinical and research platform for modern neurorehabilitation and brain health applications.

Cost-Effective and High-Performance Systems

While most commercially available TMS systems rely on expensive imported technologies, MagRenu™ TMS is fully designed and manufactured in Taiwan, offering:

• International-level performance standards

• High manufacturing and engineering quality

• Competitive and accessible pricing

• Localized technical support and flexible system architecture

This significantly lowers the adoption threshold for healthcare institutions and enables small- to mid-sized hospitals, specialty clinics, and private practices to efficiently integrate advanced neurostimulation services.

Clinically Validated Performance

Multiple performance evaluations and preclinical assessments have demonstrated that MagRenu™ TMS delivers excellent performance and reliability across critical technical parameters, including:

• Magnetic field stability

• Treatment parameter accuracy

• Stimulation reproducibility and consistency

MagRenu™ TMS has attracted strong interest from leading medical centers and specialist clinical teams, who have conducted on-site system evaluations and clinical feasibility assessments, further strengthening confidence in its real-world clinical performance.

Our Mission

Driven by the mission “Safeguarding Brain Health Through Technology,” Vision ReNu Corp. is committed to empowering physicians and research institutions with:

• Safe

• Effective

• Affordable

• Clinically meaningful neuromodulation solutions

Our goal is to improve patient outcomes, enhance quality of life, and reduce the long-term socioeconomic burden of neurological and psychiatric disorders worldwide.